Therapeutic approaches and vaccination in fighting COVID-19 infections : A review
© 2022 Published by Elsevier Inc..
Coronavirus disease 2019 (COVID-19) is a remarkably contagious and pathogenic viral infection arising from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan, China. For the time being, COVID-19 is not treated with a specific therapy. The Food and Drug Administration (FDA) has approved Remdesivir as the first drug to treat COVID-19. However, many other therapeutic approaches are being investigated as possible treatments for COVID-19. As part of this review, we discussed the development of various drugs, their mechanism of action, and how they might be applied to different cases of COVID-19 patients. Furthermore, this review highlights an update in the emergence of new prophylactic or therapeutic vaccines against COVID-19. In addition to FDA or The World Health Organization (WHO) approved vaccines, we intended to incorporate the latest published data from phase III trials about different COVID-19 vaccines and provide clinical data released on the networks or peer-review journals.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Gene reports - 27(2022) vom: 28. Juni, Seite 101619 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Adibzadeh, Setare [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 16.07.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.genrep.2022.101619 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340591870 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340591870 | ||
| 003 | DE-627 | ||
| 005 | 20231226005710.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.genrep.2022.101619 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1135.xml |
| 035 | |a (DE-627)NLM340591870 | ||
| 035 | |a (NLM)35530725 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Adibzadeh, Setare |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Therapeutic approaches and vaccination in fighting COVID-19 infections |b A review |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 Published by Elsevier Inc. | ||
| 520 | |a Coronavirus disease 2019 (COVID-19) is a remarkably contagious and pathogenic viral infection arising from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan, China. For the time being, COVID-19 is not treated with a specific therapy. The Food and Drug Administration (FDA) has approved Remdesivir as the first drug to treat COVID-19. However, many other therapeutic approaches are being investigated as possible treatments for COVID-19. As part of this review, we discussed the development of various drugs, their mechanism of action, and how they might be applied to different cases of COVID-19 patients. Furthermore, this review highlights an update in the emergence of new prophylactic or therapeutic vaccines against COVID-19. In addition to FDA or The World Health Organization (WHO) approved vaccines, we intended to incorporate the latest published data from phase III trials about different COVID-19 vaccines and provide clinical data released on the networks or peer-review journals | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ACE2, Angiotensin-converting enzyme 2 | |
| 650 | 4 | |a ARDS, Acute respiratory distress syndrome | |
| 650 | 4 | |a Antiviral agents | |
| 650 | 4 | |a Arb, Arbidol | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19, Coronavirus disease 2019 | |
| 650 | 4 | |a ER, Endoplasmic reticulum | |
| 650 | 4 | |a ERGIC, Endoplasmic reticulum Golgi intermediate compartment | |
| 650 | 4 | |a FDA, Food and Drug Administration | |
| 650 | 4 | |a HIV, Human immunodeficiency virus | |
| 650 | 4 | |a MERS-CoV, The Middle East respiratory syndrome 20 coronavirus | |
| 650 | 4 | |a ORFs, Open reading frames | |
| 650 | 4 | |a Pandemics | |
| 650 | 4 | |a Pneumonia | |
| 650 | 4 | |a RBD, Receptor binding domain | |
| 650 | 4 | |a RTC, Replicase transcriptase complex | |
| 650 | 4 | |a RdRp, RNA-dependent RNA polymerase | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a SARS-CoV-2, Severe acute respiratory syndrome of coronavirus 2 | |
| 650 | 4 | |a VLPs, Virus-like particles | |
| 650 | 4 | |a Vaccines | |
| 650 | 4 | |a WHO, World Health Organization | |
| 650 | 4 | |a WMT, Washed microbiota transplantation | |
| 650 | 4 | |a gRNA, Genomic RNA | |
| 650 | 4 | |a mAbs, Monoclonal antibodies | |
| 650 | 4 | |a sgRNA, Subgenomic RNA | |
| 700 | 1 | |a Amiri, Shahin |e verfasserin |4 aut | |
| 700 | 1 | |a Nia, Giti Esmail |e verfasserin |4 aut | |
| 700 | 1 | |a Taleghani, Maryam Rezakhani |e verfasserin |4 aut | |
| 700 | 1 | |a Bijarpas, Zahra Kohanrooz |e verfasserin |4 aut | |
| 700 | 1 | |a Maserat, Neda |e verfasserin |4 aut | |
| 700 | 1 | |a Maali, Amirhosein |e verfasserin |4 aut | |
| 700 | 1 | |a Azad, Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Behzad-Behbahani, Abbas |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gene reports |d 2016 |g 27(2022) vom: 28. Juni, Seite 101619 |w (DE-627)NLM263779483 |x 2452-0144 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2022 |g day:28 |g month:06 |g pages:101619 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.genrep.2022.101619 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2022 |b 28 |c 06 |h 101619 | ||